176 related articles for article (PubMed ID: 38260426)
21. The metabotropic glutamate receptor 5 negative allosteric modulator fenobam: pharmacokinetics, side effects, and analgesic effects in healthy human subjects.
Cavallone LF; Montana MC; Frey K; Kallogjeri D; Wages JM; Rodebaugh TL; Doshi T; Kharasch ED; Gereau RW
Pain; 2020 Jan; 161(1):135-146. PubMed ID: 31568235
[TBL] [Abstract][Full Text] [Related]
22. Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats.
D'Amore V; Santolini I; Celli R; Lionetto L; De Fusco A; Simmaco M; van Rijn CM; Vieira E; Stauffer SR; Conn PJ; Bosco P; Nicoletti F; van Luijtelaar G; Ngomba RT
Neuropharmacology; 2014 Oct; 85():91-103. PubMed ID: 24859611
[TBL] [Abstract][Full Text] [Related]
23. Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons.
Salt TE; Binns KE
Neuroscience; 2000; 100(2):375-80. PubMed ID: 11008175
[TBL] [Abstract][Full Text] [Related]
24. Peripheral nerve injury reduces the excitation-inhibition balance of basolateral amygdala inputs to prelimbic pyramidal neurons projecting to the periaqueductal gray.
Cheriyan J; Sheets PL
Mol Brain; 2020 Jun; 13(1):100. PubMed ID: 32600466
[TBL] [Abstract][Full Text] [Related]
25. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors.
Homayoun H; Moghaddam B
Cereb Cortex; 2006 Jan; 16(1):93-105. PubMed ID: 15843630
[TBL] [Abstract][Full Text] [Related]
26. Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1.
Kiritoshi T; Sun H; Ren W; Stauffer SR; Lindsley CW; Conn PJ; Neugebauer V
Neuropharmacology; 2013 Mar; 66():170-8. PubMed ID: 22521499
[TBL] [Abstract][Full Text] [Related]
27. Blocking glutamate mGlu
Milanese M; Bonifacino T; Torazza C; Provenzano F; Kumar M; Ravera S; Zerbo AR; Frumento G; Balbi M; Nguyen TPN; Bertola N; Ferrando S; Viale M; Profumo A; Bonanno G
Br J Pharmacol; 2021 Sep; 178(18):3747-3764. PubMed ID: 33931856
[TBL] [Abstract][Full Text] [Related]
28. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
[TBL] [Abstract][Full Text] [Related]
29. Interaction between Ephrins and mGlu5 metabotropic glutamate receptors in the induction of long-term synaptic depression in the hippocampus.
Piccinin S; Cinque C; Calò L; Molinaro G; Battaglia G; Maggi L; Nicoletti F; Melchiorri D; Eusebi F; Massey PV; Bashir ZI
J Neurosci; 2010 Feb; 30(8):2835-43. PubMed ID: 20181581
[TBL] [Abstract][Full Text] [Related]
30. Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.
Fu TT; Tu G; Ping M; Zheng GX; Yang FY; Yang JY; Zhang Y; Yao XJ; Xue WW; Zhu F
Acta Pharmacol Sin; 2021 Aug; 42(8):1354-1367. PubMed ID: 33122823
[TBL] [Abstract][Full Text] [Related]
31. Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia.
Sciamanna G; Ponterio G; Tassone A; Maltese M; Madeo G; Martella G; Poli S; Schirinzi T; Bonsi P; Pisani A
Neuropharmacology; 2014 Oct; 85():440-50. PubMed ID: 24951854
[TBL] [Abstract][Full Text] [Related]
32. A novel rat medial prefrontal cortical slice preparation to investigate synaptic transmission from amygdala to layer V prelimbic pyramidal neurons.
Orozco-Cabal L; Pollandt S; Liu J; Vergara L; Shinnick-Gallagher P; Gallagher JP
J Neurosci Methods; 2006 Mar; 151(2):148-58. PubMed ID: 16154203
[TBL] [Abstract][Full Text] [Related]
33. Differential Modulation of Thresholds for Intracranial Self-Stimulation by mGlu5 Positive and Negative Allosteric Modulators: Implications for Effects on Drug Self-Administration.
Cleva RM; Watterson LR; Johnson MA; Olive MF
Front Pharmacol; 2012; 2():93. PubMed ID: 22232603
[TBL] [Abstract][Full Text] [Related]
34. Metabotropic glutamate receptor, mGlu5, regulates hippocampal synaptic plasticity and is required for tetanisation-triggered changes in theta and gamma oscillations.
Bikbaev A; Manahan-Vaughan D
Neuropharmacology; 2017 Mar; 115():20-29. PubMed ID: 27395786
[TBL] [Abstract][Full Text] [Related]
35. The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine.
Montana MC; Cavallone LF; Stubbert KK; Stefanescu AD; Kharasch ED; Gereau RW
J Pharmacol Exp Ther; 2009 Sep; 330(3):834-43. PubMed ID: 19515968
[TBL] [Abstract][Full Text] [Related]
36. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.
Gould RW; Amato RJ; Bubser M; Joffe ME; Nedelcovych MT; Thompson AD; Nickols HH; Yuh JP; Zhan X; Felts AS; Rodriguez AL; Morrison RD; Byers FW; Rook JM; Daniels JS; Niswender CM; Conn PJ; Emmitte KA; Lindsley CW; Jones CK
Neuropsychopharmacology; 2016 Mar; 41(4):1166-78. PubMed ID: 26315507
[TBL] [Abstract][Full Text] [Related]
37. Control of Theta Oscillatory Activity Underlying Fear Expression by mGlu
Matulewicz P; Ramos-Prats A; Gómez-Santacana X; Llebaria A; Ferraguti F
Cells; 2022 Nov; 11(22):. PubMed ID: 36428984
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo(1.1.1)pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity.
Mannaioni G; Attucci S; Missanelli A; Pellicciari R; Corradetti R; Moroni F
Neuropharmacology; 1999 Jul; 38(7):917-26. PubMed ID: 10428410
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic Insights into Light-Driven Allosteric Control of GPCR Biological Activity.
Ricart-Ortega M; Berizzi AE; Pereira V; Malhaire F; Catena J; Font J; Gómez-Santacana X; Muñoz L; Zussy C; Serra C; Rovira X; Goudet C; Llebaria A
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):883-895. PubMed ID: 33073188
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats.
D'Amore V; Santolini I; van Rijn CM; Biagioni F; Molinaro G; Prete A; Conn PJ; Lindsley CW; Zhou Y; Vinson PN; Rodriguez AL; Jones CK; Stauffer SR; Nicoletti F; van Luijtelaar G; Ngomba RT
Neuropharmacology; 2013 Mar; 66():330-8. PubMed ID: 22705340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
